ABSTRACT -Background -Celiac disease is an immune-mediated disorder with a multiform presentation and therefore a challenging diagnosis. Objective -Our purpose is to identify the epidemiological, clinical, laboratory and histologic characteristics of children with celiac disease at diagnosis and on follow-up. Methods -Children with previously established or newly diagnosed celiac disease, admitted in a tertiary centre in a two-year period (2014)(2015)(2016) were recruited. Data was collected retrospectively from electronic medical records and clinical notes, and subsequently analysed with SPSS version 20.0. Results -A total of 159 patients, out of 312, were included. Age ranged from 1 to 17 years (mean ± SD: 8.5±4.5 years, 69% girls). Disease presentation was classical in 60%, non-classical in 25%, subclinical in 10% and 5% classified as potential celiac disease. Non-classical and subclinical profiles had a higher mean age at presentation but not statistically significant (P-value 0.24). The most frequent gastrointestinal features at presentation were abdominal pain (58%), diarrhea (43%) and bloating (27%). A positive family history for celiac disease was present in 24% (n=35). We found anaemia in 23%, low ferritin in 63% and a moderate to severe deficiency of 25-hydroxyvitamin D in 62%. celiac disease -specific serologic testing and esophagogastroduodenoscopy were performed in 99%. Histology revealed modified Marsh 2 or 3 enteropathy in 94%, the remaining had normal histology but positive human leukocyte antigen typing. Clinical improvement at 12 months of gluten-free diet was complete in 51% and partial in 49%. IgA tTG normalized after 12-30 months of gluten-free diet in 45%. On growth assessment at diagnosis and after 12-28 months of gluten-free diet, 100% had height increase (mean ±SD: 7.11±4.43 cm) and 96% weight gain (mean ±SD: 5.60±4.91 kg). Conclusion -Our findings outline the diverse clinical presentations of pediatric celiac disease that should be considered irrespective of age. Increased clinician's awareness will enable an early diagnosis and treatment, with subsequent symptom and nutritional status improvement.
INTRODUCTION
Celiac disease (CD) is a chronic small intestine immune-mediated disorder elicited by the ingestion of gluten in genetically predisposed individuals. In the United States and in Europe, the prevalence ranges from 1:300 to 1:500 (1) , and in UK is estimated to be 1:100 (2) . The universal screening is not currently being advised. However, awareness should be raised and there should be a low threshold for investigating both symptomatic children and those with associated conditions, as it is known that approximately 90% of cases remain undiagnosed (2) . The CD is commonly detected in patients with diarrhea, but the clinical manifestations of CD are numerous and vary from none (asymptomatic) to a broad spectrum of gastrointestinal symptoms and extraintestinal manifestations. These different modes of presentation, lead experts to elaborate the Oslo Classification (3) , which subdivides CD into symptomatic CD, includes the "classical" and "non-classical" presentations, versus the "asymptomatic" or "subclinical" CD. The classic CD presents with signs and symptoms of malabsorption and the non-classic CD is characterized by other gastrointestinal symptoms apart from diarrhea and extra-intestinal symptoms. The subclinical CD is below the threshold of clinical detection. There is also the "potential CD" describing the patients at risk of developing the disease in the future.
In this study, we retrospectively examined the clinical presenta-indicated. Histological findings in small intestine biopsies, taken from the bulb or the second duodenal portion, were classified according to the Modified Marsh Classification by Oberhuber (4) . Serology included mainly immunoglobulin A tissue transglutaminase antibodies (IgA tTG) as the first option, immunoglobulin A anti-endomysial antibodies (IgA EMA) if the first was weakly positive or not available and immunoglobulin G tissue transglutaminase antibodies (IgG tTG), immunoglobulin G anti-endomysial antibodies (IgG EMA) or immunoglobulin G anti-gliadin antibodies (IgG AGA) in the case of IgA deficiency (5) . The histopathology findings of crypt hyperplasia (lesion type 2) with villous atrophy (includes partial -type 3a, subtotal -type 3b and total atrophy -type 3c), associated or not with a positive serology, confirmed the diagnosis of CD. Additionally, according to the European Society for Pediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guideline for the diagnosis of CD (6) , in cases with IgA tTG levels at least 10 times higher the upper reference limit along with positivity for EMA antibodies and HLA testing would also confirm the diagnosis. On the other hand, cases with positive serology and normal or mild duodenal lesions (increased intra-epithelial lymphocytes -lesion type 1) would be classified as potential CD if HLA testing was positive.
Regarding the clinical phenotype, according to the Oslo Classification, patients were divided in: 1) classical CD with a malabsorptive syndrome, presenting with diarrhea, steatorrhea, weight loss or growth failure as a requirement; 2) non-classical CD presents with gastrointestinal symptoms (except for diarrhea or steatorrhea) and extraintestinal manifestations; 3) subclinical CD for asymptomatic cases or with symptoms considered to be below the threshold for detection; 4) potential CD for patients with a normal intestinal mucosa who are at increased risk of developing CD as indicated by a positive serology (3) . In this study in particular, we classified the patient as potential CD, only if, additionally, the HLA DQ2 and/ or HLA DQ8 tested positive.
Statistical analysis
Data collection and all the statistical analysis were performed on SPSS Statistics version 20.0 for Macintosh (Armonk, NY: IBM Corp.), using absolute and relative frequencies for categorical variables, means and standard deviation (SD) for continuous variables, ANOVA test for variance analysis and Fisher's exact tests were used to compare independent data. A significance level of P<0.05 was considered.
RESULTS
One hundred and fifty-nine patients out of the three hundred and twelve initially elected were included (FIGURE 1). The mean age at diagnosis was 8.5±4.5 years (range 1.1 to 17.7 years) and 69% were females. Eleven patients (6.9%) were less than 2 years of age (FIGURE 2). Family history (n=147) was positive for CD in 24% (TABLE 1) . Mean age and standard deviation (x _ ±SD) values at presentation were calculated for the four types of CD (FIGURE 3). The classical presentation occurred in 59.7%, non-classical in 25.2%, subclinical in 10.1% and potential CD in 5.0%, as shown on TABLE 2. On comparison, subclinical and non-classical groups had a higher mean age at presentation, but not statiscally significant on ANOVA test (P-value 0.24). The box plot shows how all the groups overlap and explains the absence of age-specific differences with respect to clinical presentation (FIGURE 3). One hundred and forty three children (n=143) presented with symptoms and 59% had 3 or more presenting symptoms. The remaining sixteen subclinical cases were asymptomatic and half presented with unexplained anemia and/or ferritin deficiency. Abdominal pain (64.3%) was the most common reported symptom at presentation (TABLE 2), followed by diarrhea (48.3%), bloating (30.1%), constipation (25.9%), weight loss (32.2%), failure to thrive and lethargy (22.4% each). Less frequently reported gastrointestinal symptoms were vomiting (19.6%), nausea (12.6%) and feces with blood or mucous (10.5%). Less common extra-intestinal symptoms included anorexia (18.9%) and irritability (7.7%). Out of the symptomatic children, 44 were aged less than five (preschool) and 99 had five years or greater. TABLE 3 displays the number of subjects with each symptom and the numbers in brackets describe the percentage of the age group with that symptom. The most common presenting symptoms in younger children (<5 years) were diarrhea (63.6%) and bloating (59.1%), yielding both a significant difference in Fisher's exact test (P<0.05). In older children (≥5 years), also with a statistically significant association, the most common presenting feature was abdominal pain (75.8%). At the time of CD diagnosis, we identified several associated conditions, as shown in TABLE 4. Type 1 diabetes mellitus (T1D, 9.4%) was the leading immunological disorder, followed by IgA deficiency (5.0%) and hypothyroidism (4.4%). T1D occurred first in 88% of the 16 patients with both CD and T1D diagnosis. Atopy (27%) was a common finding. Thirteen patients had neurodevelopment disorders (8.2%). Migraine (3.1%) was the main neurological condition and anxiety (2.5%) the most common psychological disorder. Rheumatological and connective tissue conditions affected twelve patients, 3.1% had joint hypermobility syndrome and 2.5% juvenile idiopathic arthritis. Seven patients had a genetic syndrome. Eosinophilic esophagitis (1.9%) was the main associated gastrointestinal disorder.
Serological testing and duodenal biopsy were both performed in 99.4% of patients (TABLE 5) . IgA tTG was the most frequently requested serological testing (86.7%). We had access to 132 esophagogastroduodenoscopy (EGD) reports; of which 73% had a modified Marsh enteropathy type 3, 5.7% type 2 and 5.1% had no findings (potential CD patients). Six out of the 14 cases with HLA typing were both HLA DQ2/DQ8 positive. All potential CD patients had a positive genetic testing. Routine blood tests showed anaemia in 23.3% (TABLE 6 ). The 25-hydroxyvitamin D analysis (n=55) revealed a moderate to severe deficiency in 62% and ferritin levels (n=75) were low in 63%. At 12 months of GFD (n=75), 51% reported a complete resolution of symptoms, 49% partial improvement and none of them mentioned no improvement or worsening of symptoms. In terms of serological response (n=42), we compared IgA tTG levels at diagnosis and after 12 to 30 months (15.57±4.53) on GFD and observed that the antibody titre normalized in 45% (<6.9 U/mL), decreased half or more in 40.5%, increased in two cases and had no change in three cases. The last five cases had a very poor compliance documented.
On growth assessment (n=57), at presentation and after 12-28 months on GFD (15.49±4.32), 100% thrived with a mean height increase of 7.11±4.43 cm and 96% gained weight, a mean of 5.60±4.91 kg. All the 159 patients were referred to a nutritionist.
DISCUSSION
The children included in this retrospective review presented with a wide variety of clinical features. Abdominal pain and diarrhea were the most common gastrointestinal symptoms at presentation and weight loss followed by failure to thrive were, not surprisingly, the main extra-intestinal findings. We found an increased prevalence of CD amongst females compared to males, in accordance with results in the literature (7) . Considering that the variable clinical picture of CD is related to both genetical and immunological bases, the age of onset may influence the clinical manifestation of the disease. We found a higher mean age at presentation on the subclinical and non-classical groups and, though it was not statistically significant, it could be associated to a delay in the recognition of the silent and atypical cases. According to the results of Bardella et al., the prevalence of the non-classic CD presentation increased with age, from 10.7% in children with less than 2 years, to 28.2% if 2 to 14 years and to 61.1% in subjects more than 14 years (8) .
The leading clinical manifestations of CD in younger children were diarrhea and bloating and older children more commonly presented with abdominal pain. Even though abdominal pain is a frequent symptom in older children with CD, there is no association between classical recurrent abdominal pain and coeliac disease (9) . All patients had a full blood count taken at the time of diagnosis and anemia was identified in 23% of the total. Anemia prevalence at disease presentation is high and comparable to available data, ranging from 9%-18% (10, 11) . Unfortunately, only 47% of subjects in our study had blood taken for ferritin. Thus the true prevalence of iron deficiency in our population is uncertain. In half of our asymptomatic cases, the only clue for CD diagnosis was the persistent anemia and/or ferritin deficiency. A prospective study, from Howard et al., recorded a 5% CD prevalence in a group of 333 children with iron and/or folate deficiency (12) . Only one third of our patients had a 25-hydroxyvitamin D assessment at diagnosis and 62% of them had a moderate to severe deficiency. Vitamin D deficiency is common in children with newly diagnosed CD, with a reported prevalence up to 27% (10, 13, 14) . A recent retrospective study by Wessels et al., including 182 children, reported that micronutrient assessment is relevant at the time of CD diagnosis, but has little diagnostic yield during followup consultations once the patient is started on a GFD (10) . The association between CD and autoimmune disorders is well known, due to shared pathological and genetical mechanisms. There is a possibility of genetic susceptibility to autoimmunity through IL-2 and IL-21 locus, both inside and outside de HLA region (7) . The prevalence of CD in children with T1D has been estimated at 15% (15) . Time course-studies on the diagnosis of T1D and CD suggests that the diagnosis of T1D usually occurs first, followed by CD (16, 17) . Our study reflects this tendency as T1D was diagnosed first in 88% of our patients with CD and T1D. In these patients, GFD might improve glycemic control and protect patients against development of diabetes-related vascular complications (18) . Overall, the reported prevalence of autoimmune thyroid impairment in pediatric patients with CD ranges from 20.4% to 41.1% (19, 20) and its clinical course does not appear to be influenced by a gluten-free diet (21) . In most CD patients with autoimmune thyroiditis, the immune response against the target cell destroys the thyroid gland gradually, leading to hypofunction. The prevalence of hypothyroidism in our patients (4.4%) is similar to the one obtained by Ansaldo et al. (4.7%) (22) . It has been shown that atopy is found in coeliac patients, but it is still unclear whether this coexistence is to be considered coincidental or an expression of a real association. Several case-control studies (23, 24) failed to demonstrate an increased prevalence of atopic conditions in children with CD when compared to controls. On the other hand, Kero et al. (25) reported a cumulative incidence of asthma in children with CD (24.6%) significantly higher than in children without CD (3.4%; P<0.001) and Ress et al. (26) showed that CD prevalence in children with active atopic dermatitis was more than four times as high as in randomly selected children. Some studies have suggested that the association between CD (T-helper cell type 1 disease) and atopy (T-helper cell type 2 disease) may be the result of vitamin D deficiency and subsequently insufficient Treg-cell capacity and shared risk factors (27, 28) . Neurological disease and behavioral symptoms also appear to be common in children with CD and are occasionally the initial clinical manifestation. We found an autism spectrum disorder (ASD) prevalence of 2.5% in our series, comprising three patients with autism and one with Asperger syndrome. Our finding could be significant, considering that just a few case reports (29, 30) mention a direct association between autism and CD, while case-control studies failed to do so (31, 32) . Nevertheless, there are several studies that have found familial autoimmunity to be a risk factor for autism (33) (34) (35) (36) . We also identified five children with migraine, four with anxiety and two with mood swings. In a study of children with newly diagnosed CD, approximately 20% had subclinical neurological abnormalities such as peripheral polyneuropathy and cortical atrophy (37) . A recent study showed that 3.5-year-old children with persistently positive tTG antibodies on a gluten-containing diet were more likely to manifest behavioral problems, including anxiety, depression and aggressiveness, when compared to those with negative antibody tests (38) . The pathogenesis of the neurologic symptoms is unclear but they tend to resolve on a GFD (39) (40) (41) . The risk of having CD is increased in children with specific genetic disorders. We found a child with Down and another with Turner syndrome. The prevalence of CD ranges from 3.2% to 10.3% in children with Down syndrome (42) (43) (44) (45) , from 2% to 10% in Turner syndrome (46) and is estimated to be 9.5% in Williams-Beuren (47) . Additionally, we spotted two cases diagnosed with CD and Joubert Syndrome (JS), both with cerebellar ataxia and neurodevelopmental delay. CD (OMIM# 212750) is associated with an increased susceptibility to cerebellar ataxia (48) , but an association with JS seems unlikely when we consider the different pathogenic mechanisms involved. In JS there is dysgenesis of the cerebellar vermis (49) , while in CD an immune-mediated neurotoxicity has been proposed (50, 51) . To the best of our knowledge no study has previously described an association of CD with JS. Also, a correlation between three other identified syndromes, Hallermann-Strieff, Crouzon and 18q deletion, and CD was not found in the literature.
The association between eosinophilic esophagitis (EoE) and CD remains controversial, with studies yielding different results (52, 53) . We found a prevalence of EoE of 1.9% in our case series, but a prevalence ranging from 3.2% to 10% has been described (52, 54, 55) . Thus in children with suspected CD undergoing EGD, obtaining routine esophageal biopsies might be advisable (52, 54, 55) . Also, the lack of validity of the currently available studies prevent us from unequivocally exclude this association (56) . Three of our patients had an inflammatory bowel disease (IBD). Some reports have shown an association between CD and IBD (57) (58) (59) (60) , but only a few pediatric studies are available. A case-control study by Virta et al. reported a higher frequency of CD (2.2%) in a group of 595 children with IBD, when compared to the general population (0.5-0.7%) (61) . However, a cohort by El-Matary et al., with a smaller population of 164 children with IBD, found no difference on CD prevalence when compared to the control group (62) . Thus, additional pediatric studies are needed to further clarify common pathways between these two immune-mediated diseases.
Apart from Sjogren's syndrome, research on CD-associated connective tissue disorders (CTD) is scarce and comprises mostly case-control studies or individual cases. The joint hypermobility syndrome (JHS), a commonly underdiagnosed heritable CTD possibly related to CD (63) (64) (65) , was present in 3.1% of our patients. The mixed connective-tissue disease (MCTD), an overlap of systemic lupus erythematosus (SLE), scleroderma and myositis, previously described in association to CD (66) , affected only one patient. Osteogenesis imperfecta (OI), an autosomal dominant hereditary disease defined by bone frailty and CTD was present in one of our patients with generalized osteopenia. Although an association is not proven yet, the coexistence of OI and CD has been described (67) . Regardless, it is convenient to rule out the presence of CD, as the clinical improvement on GFD might be considerable.
There are several studies on the association between CD and joint manifestations (68) (69) (70) , but only a few describe the connection to the inflammation involving the entheses (insertions of tendons and ligaments) (71) (72) (73) , which is an early feature of this process that is frequently missed during clinical evaluation. We found a case of Achilles tendinitis and plantar fasciitis that jointly comprise the enthesitis. The literature shows conflicting results on the impact of GFD, with some achieving a complete remission while others have no response (71, 72) . The juvenile idiopathic arthritis (JIA) encompasses different forms of chronic arthritis in children, all characterized by joint pain and inflammation (74) . We found four patients with CD and JIA, accounting for 2.5% of cases. The prevalence of JIA in children with CD is not clearly outlined. Conversely, the reported prevalence of CD in children presenting with JIA ranges between 2.5% and 6.6% (75, 76) . There is strong evidence confirming an increased risk of dental enamel defects (DED) in children with CD and it may be the only presenting symptom (1, 77) . The incisors and molars are the most frequently affected (77) (78) (79) . We report a 2.5% prevalence of DED, but three case-control studies have reported estimates of 55%, 62% and 73% (as compared with 18%, 21% and 0% in the corresponding control groups), indicating higher prevalence of DED among children with CD (77) (78) (79) . A significant improvement on GFD in children with DED and CD is reported, so screening for CD is highly recommended, particularly in the presence of hypocalcemia (78, 80) . Not surprisingly we found a case of dermatitis herpetiformis (DH), which is considered as the specific cutaneous expression of gluten intolerance and the most common skin manifestation of CD (81) (82) (83) . The suspicion of DH should prompt screening for CD and the first-line therapy is GFD (81, 82) . We have been able to find one case of psoriasis and one of erythema nodosum (EN). Several studies support an increased risk of psoriasis in patients with CD and report the positive impact of GFD on skin lesions (84, 85) . However, this association remains controversial due to the few data currently available. Similarly, the available evidence supporting the association of CD with EN is very limited and based exclusively on single case reports in which patients become asymptomatic on a GFD (86, 87) . We suggest that a serological evaluation for CD should be considered in patients with psoriasis and EN, particularly in non-responders to first-line therapies.
Even though the current study retrospectively describes relevant data on English children with CD, we recognize its limitations. The selected children with CD attended a tertiary referral centre and this could result in a selection bias due to the fact that those patients probably have more severe disease and associated conditions. The large number of repeated admissions excluded from our study population (n=109) were not considered or analyzed, since most patients were clinically stable and being admitted for multidisciplinary follow-up clinics. Also, the retrospective nature of this study explains the lack of availability of specific measures and data.
To conclude, we present a wide variety of celiac disease presentations and related conditions, some yet to be confirmed, so it should be noticed that further studies in the pediatric population with larger samples are needed to reliably corroborate identified associations and to clarify if the age at presentation is a determinant of clinical features in CD.
CONCLUSION
These findings outline the diverse clinical presentations of paediatric CD that should be considered irrespective of age. A classical symptom-based case finding is insufficient to identify a vast number of children with non-classic manifestations of CD who are likely to report to specialists other than gastroenterologists. The universal screening is not currently being advised, which emphasizes the importance of raising awareness amongst health care professionals to the different clinical presentations of the disease and the associated autoimmune conditions. A comprehensive approach to CD will enable an early recognition and treatment, with subsequent symptom relief and nutritional status optimization.
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